STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio Strengthens Board Ties with Major Equity Package to Director Cook

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma director Jennifer E. Cook received new equity compensation grants on June 20, 2025, consisting of:

  • 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing her total direct RSU ownership to 13,741 shares
  • 8,425 Stock Options with an exercise price of $41.73 per share, expiring June 19, 2035

Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Cook's continued service as a director. This Form 4 filing, signed on June 24, 2025, reflects standard equity compensation for non-employee directors and demonstrates the company's approach to aligning director interests with shareholders through long-term equity incentives.

Positive

  • None.

Negative

  • None.
Insider Cook Jennifer E.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 8,425 $0.00 $0.00
Grant/Award Common Stock 6,589 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 8,425 shares (Direct); Common Stock — 13,741 shares (Direct)
Footnotes (3)
  1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
  2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  3. F3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

How many shares did BBIO director Jennifer Cook acquire on June 20, 2025?
Jennifer Cook acquired 6,589 restricted stock units (RSUs) and 8,425 stock options of BBIO on June 20, 2025. The RSUs represent a right to receive an equal number of common shares.

What is the exercise price of BBIO stock options granted to Jennifer Cook?
The stock options granted to Jennifer Cook have an exercise price of $41.73 per share and expire on June 19, 2035.

What is the vesting schedule for BBIO's RSUs and stock options granted to Jennifer Cook?
Both the RSUs and stock options vest over three years, with one-third vesting each year after June 20, 2025. Full vesting will occur on June 20, 2028, subject to Cook's continued service on BBIO's board of directors.

How many BBIO shares does Jennifer Cook own directly after the June 20, 2025 transaction?
Following the reported transaction, Jennifer Cook directly owns 13,741 shares of BBIO common stock, plus 8,425 stock options and 6,589 unvested RSUs.

What is Jennifer Cook's role at BBIO according to the Form 4?
According to the Form 4 filing, Jennifer Cook serves as a Director on BBIO's board of directors. This is indicated by the 'X' marked in the Director box under the relationship to issuer section.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cook Jennifer E.
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 6,589 A $0(2) 13,741 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.73 06/20/2025 A 8,425 (3) 06/19/2035 Common Stock 8,425 $0 8,425 D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Jennifer E. Cook 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR